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Abstract
Background—Surveillance for acute flaccid paralysis with laboratory confirmation has been a 
key strategy in the global polio eradication initiative, and the laboratory platform established for 
polio testing has been expanded in many countries to include surveillance for cases of febrile rash 
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illness to identify measles and rubella cases. Vaccine-preventable disease surveillance is essential 
to detect outbreaks, define disease burden, guide vaccination strategies and assess immunization 
impact. Vaccines now exist to prevent Japanese encephalitis (JE) and some etiologies of bacterial 
meningitis.
Methods—We evaluated the feasibility of expanding polio–measles surveillance and laboratory 
networks to detect bacterial meningitis and JE, using surveillance for acute meningitis-encephalitis 
syndrome in Bangladesh and China and acute encephalitis syndrome in India. We developed nine 
syndromic surveillance performance indicators based on international surveillance guidelines and 
calculated scores using supervisory visit reports, annual reports, and case-based surveillance data.
Results—Scores, variable by country and targeted disease, were highest for the presence of 
national guidelines, sustainability, training, availability of JE laboratory resources, and 
effectiveness of using polio–measles networks for JE surveillance. Scores for effectiveness of 
building on polio–measles networks for bacterial meningitis surveillance and specimen referral 
were the lowest, because of differences in specimens and techniques.
Conclusions—Polio–measles surveillance and laboratory networks provided useful 
infrastructure for establishing syndromic surveillance and building capacity for JE diagnosis, but 
were less applicable for bacterial meningitis. Laboratory-supported surveillance for vaccine-
preventable bacterial diseases will require substantial technical and financial support to enhance 
local diagnostic capacity.
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1. Background
Strong systems for vaccine-preventable disease (VPD) surveillance are essential for making 
evidence-based decisions concerning the introduction of new vaccines. To provide a strategic 
approach for enhancing VPD surveillance and immunization program monitoring, the World 
Health Organization (WHO) and other global partners developed a Global Framework for 
Immunization Monitoring and Surveillance (GFIMS) [1]. One principle of the framework 
was to link epidemiologic and laboratory surveillance systems for all VPDs and leverage the 
investment for poliomyelitis surveillance.
Since 1985, identification of poliomyelitis cases has relied on active surveillance for acute 
flaccid paralysis (AFP) and laboratory testing of stool specimens for polioviruses [2–4]. 
Beginning in the early 1990s, many countries expanded viral VPD surveillance to facilitate 
measles case detection by adding a rash-fever syndrome case definition. Measles diagnostic 
testing capacity has been developed within poliovirus reference laboratories, and a network 
of sub-national laboratories. This polio–measles surveillance infrastructure has provided a 
platform for establishing laboratory-supported surveillance for other VPDs of viral etiology, 
including rubella and yellow fever. A survey in countries in the WHO African Region found 
that adding other VPDs to the AFP surveillance program did not compromise polio 
surveillance [5].
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The availability of vaccines against diseases caused by Haemophilus influenzae type b 
(Hib), Neisseria meningitidis (Nm), and Streptococcus pneumoniae (Sp) has created the 
need to include bacterial disease surveillance in the VPD surveillance framework. Diagnosis 
of bacterial diseases, however, is more complex than that of viral diseases because of the 
need for specimen collection before starting antibiotic treatment, an invasive specimen 
collection procedure, quality laboratory capability at the specimen collection site, and 
immediate specimen transportation from the collection site to diagnostic laboratories. 
Surveillance for invasive bacterial disease (IBD) has been conducted in many countries 
primarily through sentinel hospital networks [6–10], but these systems have not been linked 
to VPD surveillance.
In 2005, the United States Centers for Disease Control and Prevention (USCDC) and WHO 
proposed using polio–measles surveillance networks to establish case-based acute 
encephalitis syndrome (AES) surveillance in India and acute meningitis-encephalitis 
syndrome (AMES) surveillance in Bangladesh and China. These countries were selected 
because of strong networks for surveillance and laboratory confirmation of polio and 
measles; these syndromes were selected because they may be manifestations of several 
VPDs, including those caused by Japanese encephalitis (JE) virus, Sp, Hib or Nm. Available 
vaccines that protect against these diseases include multiple formulations of JE vaccine, 
multivalent pneumococcal conjugate vaccines (PCV), monovalent and combination Hib 
vaccines, and polysaccharide and conjugate meningococcal vaccines [11–14]. None of the 
countries had introduced PCV, JE, Hib or meningococcal vaccines into their routine 
immunization programs, although China provided routine and/or campaign vaccination in 
some provinces.
Data on JE and bacterial meningitis incidence in Bangladesh, China and India are limited. In 
Bangladesh, JE virus appears to be endemic throughout the country [15,16]. In China, 
approximately 33,900 cases of JE occur annually [17]. JE is endemic throughout much of 
India with large seasonal outbreaks documented in several states in northern India [18,19]. 
Although meningitis caused by Sp, Hib and Nm has been greatly reduced in countries where 
vaccines against these pathogens are routinely used [20], cases continue to occur in 
Bangladesh, China, and India. In Bangladesh, meningitis caused by Sp and Hib has been 
monitored through sentinel surveillance networks [10,21,22]. Outbreaks of meningococcal 
meningitis and septicemia were reported in China from 2003 to 2005 [23]. In Vellore 
District in the Indian state of Tamil Nadu, the estimated annual Hib meningitis incidence 
was 7.1 cases per 100,000 children <5 years of age, comparable to rates reported from 
Europe before Hib vaccine introduction [24].
AMES surveillance was launched by Ministries of Health (MOH) in China in May 2006 and 
in Bangladesh in October 2007 using the infrastructure of the polio–measles surveillance 
and laboratory networks. Because of India’s priority to identify best practices to improve 
AES surveillance, meningitis surveillance was not included in India; AES surveillance 
started in May 2007. Project areas included three sentinel hospitals (one in each of three 
districts) in Bangladesh, 24 (six in each of four prefectures) in China and four (one in each 
of four JE-endemic states) in India (Fig. 1). Criteria for selection of project areas included 
the absence of wild poliovirus circulation and meeting the global indicators for rates of non-
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polio AFP and adequate stool collection6 [25]. Details and data of the AMES–AES 
surveillance systems are described elsewhere [16,26–31]. The purpose of this paper is to 
evaluate the feasibility of expanding polio–measles surveillance and laboratory networks to 
detect bacterial meningitis and JE, using surveillance for acute meningitis-encephalitis 
syndrome in Bangladesh and China and acute encephalitis syndrome in India.
2. Methods
Countries established active surveillance for clinically recognizable characteristics and 
symptoms at sentinel hospitals. An AMES case was defined as the acute onset of fever in a 
person of any age at any time of year, accompanied by a change in mental status, or new 
onset seizures (excluding simple febrile seizures), or meningeal signs or neck stiffness [32]. 
The AES case definition did not include meningeal signs or neck stiffness. Cerebrospinal 
fluid (CSF) and blood specimens were collected from all identified AMES and AES case–
patients and tested for JE IgM by enzyme-linked immunosorbent assay (ELISA). CSF 
specimens from AMES case–patients were also tested for bacterial meningitis by bacterial 
culture and latex agglutination (for Hib, Nm serogroups and Sp) where available, and CSF 
and sera by real-time polymerase chain reaction (PCR). If specimen quantity permitted, the 
primary sentinel site laboratory referred aliquots to secondary and tertiary laboratories for 
quality control and advanced testing.
To evaluate AMES and AES surveillance, we developed post hoc nine qualitative indicators 
to assess implementation of surveillance and six quantitative indicators to evaluate 
performance (Box 1). Five of the nine qualitative indicators (national guidelines, monitoring, 
feedback, representativeness and sustainability) assessed the overall implementation of 
syndromic surveillance, irrespective of the target syndrome. Implementation of surveillance 
to detect JE or bacterial meningitis was evaluated through the four remaining qualitative 
indicators—training, availability of laboratory resources, data standardization and 
effectiveness of building on polio–measles networks (how readily polio–measles standard 
operating procedures [SOPs], staff, specimen shipping, engagement with hospital clinicians 
were adaptable to AMES/AES). Six quantitative indicators (data completeness, data validity, 
timeliness, specimen collection, specimen referral to secondary and tertiary laboratories) 
evaluated performance based on core surveillance attributes and activities.
We developed indicator scores by adapting quantitative criteria and targets from published 
polio–measles surveillance guidelines and recommendations and two authors (KFC, HSS) 
awarded points as described below [32–34]. Each indicator included 1–7 components. 
Components whose achievement could be measured as “yes” or “no”, were awarded points 
as follows: 1 point for “yes” and 0 points for “no” (for example, “were guidelines based on 
international standards?”). Components that could be measured for each year of 
surveillance, or had multiple criteria were worth up to 2 points (for example, “conducted 
biannual visits to sentinel sites”). For representativeness, if all health facilities in the project 
6At least one case of non-polio AFP should be detected annually per 100,000 population aged less than 15 years, and all AFP cases 
should have a full clinical and virological investigation with at least 80% of AFP cases having adequate stool specimens collected. 
Adequate stool specimens are two stool specimens of sufficient quantity for laboratory analysis, collected at least 24 h apart, within 14 
days after the onset of paralysis, and arriving in the laboratory by reverse cold chain and with proper documentation.
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area (province, district, or state) reported cases, 2 points were awarded; if an indirect 
measure of representativeness was used, such as catchment survey, 1 point was awarded.
To compute the percentages used to calculate scores, we used the number of cases that met 
the indicator target as the numerator, and the number of AMES cases detected in China 
(May 2006–September 2008), or in Bangladesh (October 2007–December 2008); or the 
number of AES cases detected in India (May 2007–December 2008) as the denominator. 
Timeliness of reporting was scored according to country guidelines for preliminary case 
reporting. It was not possible to evaluate sensitivity, as we did not have data on active case 
searches.
We used reports from supervisory visits and annual reports to calculate the indicator scores. 
In China, we reviewed semi-annual and annual case-based surveillance data, and in 
Bangladesh and India, we examined computerized epidemiological and laboratory data. We 
also analyzed a convenience sample of observations collected during field visits in India 
(autumn 2008) and Bangladesh (winter 2009) to evaluate specimen collection and transport 
practices and to assess laboratory data flow. Statistical Package for the Social Sciences 
(SPSS, IBM Corporation) was used for data analysis.
3. Results
3.1. Implementation of syndromic surveillance
In all three countries, national AMES–AES surveillance guidelines were developed based on 
WHO standards, and copies were present at sentinel sites in China and India; in Bangladesh, 
guidelines were developed at the national level, but were not distributed (Table 1). National 
program officers in all countries conducted and documented monitoring and supervisory 
visits to sentinel sites at least semiannually; international partners participated annually, 
although standard monitoring protocols were not used. Feedback to sentinel sites was 
delayed in all countries, primarily because of policies requiring the national level to wait for 
confirmation from tertiary laboratories before reporting results. In India, feedback was also 
delayed because epidemiologic and laboratory data were not readily linkable in the national 
database. China applied a population-based approach consisting of active surveillance at all 
hospitals in the prefecture and laboratory confirmation only at sentinel sites. Bangladesh 
undertook catchment surveys in project districts to provide a basis for adjusting surveillance 
data, and India conducted only sentinel surveillance. All three countries developed credible 
plans to sustain AMES and AES surveillance in at least some sentinel sites, using national 
and donor resources and funding.
3.2. Implementation of surveillance for JE and bacterial meningitis
Comprehensive training agendas for disease-specific surveillance were developed in all 
countries (Table 2). These included (1) surveillance workshops for staff at sentinel, 
intermediate and national levels; (2) laboratory workshops on WHO- and USCDC-
recommended techniques for JE IgM ELISA, bacterial culture, and, in China, on real-time 
PCR for diagnosis of bacterial meningitis; and (3) training at USCDC for senior surveillance 
and laboratory specialists in epidemiology and molecular techniques.
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JE testing equipment and initial stocks of ELISA kits were received in all project 
laboratories, but frequent shortages in Bangladesh and India limited JE testing. Provision of 
equipment and supplies for bacterial culture and PCR in China was delayed for several 
months. In Bangladesh, micro-centrifuges were not available for CSF processing in some 
hospital laboratories, necessitating the use of conventional centrifuges, which consumed 
larger specimen volumes, leaving less for other tests.
Data standardization was stronger for clinical case reporting than for laboratory reporting, 
mainly because of differences in availability of data management software and staff skilled 
in their use. For example, polio–measles surveillance staff in each project district used a 
software application (Epi Info™ [CDC, Atlanta, USA] in India and Bangladesh; EPIDATA 
[EpiData Association, Odense Denmark] in China) to create a clinical AMES and AES case 
database, while laboratory staff at sentinel sites had limited tools and experience in data 
management and reporting. Hospital laboratory staff in Bangladesh and China manually 
recorded diagnostic results and reported to the district level, where surveillance staff entered 
results into the AMES database. In India, hospital laboratory staff recorded JE ELISA 
results into a spreadsheet (MicroSoft Excel®), but lacked capability to maintain the integrity 
of the unique identifiers or manage large data sets. The spreadsheets were sent to the 
regional reference laboratory, where the results were compiled and dispatched to the national 
level. Loss of unique identifiers delayed linkage of JE laboratory data and AES surveillance 
data resulting in delayed reporting of JE test results to clinicians (per field visits).
Overall, we found polio–measles surveillance networks to be effective for developing JE and 
bacterial meningitis surveillance. All countries adapted polio–measles case investigation and 
line list formats and software for creating an AMES–AES case database; polio–measles staff 
provided technical oversight to AMES–AES sentinel sites. However, there were some 
missed opportunities to link with polio–measles surveillance. For example, none of the 
countries adapted polio–measles monitoring procedures and supervisory checklists for 
oversight of AMES–AES surveillance. While the WHO South-East Asia Regional Office 
(SEARO) expanded regional polio–measles surveillance bulletins to include AES 
surveillance data, the WHO Western Pacific Regional Office did not. Additionally, the 
strong links between surveillance officers and pediatricians forged by polio–measles 
infrastructure were not expanded to include clinicians on adult wards, who are important for 
AMES–AES surveillance. In addition, a 2006–2007 polio resurgence in India in non-AES 
areas limited the availability of national polio–measles staff to conduct surveillance [35].
Because both measles and JE testing rely on similar indirect methods, polio–measles 
protocols for handling and testing specimens, and reporting results were easily adapted and 
used for JE IgM ELISA, and laboratory staff responsible for measles diagnostic testing 
readily incorporated JE testing into their work. In addition, WHO regional polio–measles 
laboratory experts provided technical support, oversight and external quality assessment for 
JE testing. In contrast, few areas of overlap existed between testing for polio and measles 
and for bacterial meningitis. Major differences in laboratory methods, equipment and 
reagents prevented use of the same staff and quality-control procedures for both JE and 
bacterial meningitis testing.
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The major strengths in surveillance performance were data completeness, concordance in JE 
results by ELISA retesting at secondary and tertiary laboratories, timeliness of investigation 
and sentinel site reporting, collection of clinical specimens and referral of specimens to a 
secondary laboratory (Table 3). Only China met the target for complete reporting of 
discharge status and concordance of JE results by proficiency testing in both 2007 and 2008, 
only Bangladesh met the case reporting timeliness target during both years, and only India 
met the 2008 target for CSF collection. No country performed well in referral of CSF 
specimens to secondary and tertiary laboratories. In nine of 11 instances of annual variation 
in meeting performance targets, the target was met in 2007 but not in 2008. Field 
observations in Bangladesh and India suggested that clinicians sometimes did not report 
case–patients from whom CSF had not been obtained, even though the patient’s illness met 
the case definition. It was also anecdotally reported that pediatric AMES–AES cases were 
more likely than adult cases to be reported.
Barriers to CSF collection and testing were found, particularly in Bangladesh and India, 
where many patients (or their families) did not consent to lumbar puncture, particularly if 
they had been referred from another facility where venipuncture had been performed. In 
addition, patients often bore the cost of specimen collection and testing in hospital 
laboratories; this resulted in some clinicians ordering specimen collection and testing based 
on the family’s perceived ability to pay. Family members were sometimes required to 
transport clinical specimens from the patient’s bedside to the laboratory, with no control or 
monitoring of temperature or interval from collection to receipt by the laboratory. Because 
JE and bacterial meningitis tests were performed on the same specimens, but in different 
parts of the hospital laboratory, coordination was required for aliquoting and distribution.
4. Discussion
In this evaluation of AMES–AES surveillance systems in Bangladesh, China, and India, we 
found that polio–measles laboratory networks were useful for the development of JE 
diagnostic capacity, but not for confirming bacterial meningitis, primarily because of 
differences in laboratory staff and viral and bacterial testing methodologies.
Polio–measles surveillance networks provided a useful infrastructure for AMES–AES 
surveillance and permitted case detection, specimen collection and testing, and compilation 
of case-based epidemiological and laboratory data. Key features included adaptable data 
collection protocols, experienced surveillance field staff and national surveillance officers, 
and WHO regional surveillance and laboratory advisors available for guidance and 
oversight. In addition, the polio–measles laboratory network offered an appropriate platform 
for building a JE laboratory network. Similar materials and technical protocols for measles 
and JE testing facilitated equipping AMES–AES laboratories and training staff, and (at some 
laboratories) permitted use of the same physical facility and personnel for measles and JE 
testing. All the systems were functioning within 14–28 months, which was likely accelerated 
by the strong partnerships among polio–measles surveillance medical officers, pediatric 
clinicians and network laboratory staff.
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Despite these advantages, we found that the polio–measles protocols for documenting and 
reporting active case searches and conducting supervision were not used for AMES–AES 
surveillance, and bulletins for dissemination of surveillance data were only used in SEARO. 
Application of these tools might have improved data completeness, timeliness, monitoring 
and feedback for AMES–AES surveillance.
We identified several important limitations of the polio–measles surveillance systems in 
conducting AMES–AES surveillance. Because of the focus on children aged <15 years in 
case-based polio–measles surveillance, existing partnerships between surveillance medical 
officers and clinicians at sentinel sites involved only pediatric clinicians, and adult ward staff 
required a more comprehensive orientation to AMES–AES surveillance protocols. In 
addition, whereas the collection, handling and indirect testing of blood for AMES and AES 
cases were easily integrated into polio–measles systems, the collection, handling and 
transport of CSF for bacterial culture posed a multitude of logistic challenges, including 
prior treatment with antibiotics and delayed specimen transport that may have affected 
culture results. Polio–measles laboratory testing is used for program monitoring, not for 
clinical management, permitting testing to be centralized at regional or national facilities. 
The identification of bacterial causes of AMES, on the other hand, is needed rapidly for case 
management and requires on-site laboratory services. Since bacteriology requires different 
skills, equipment and reagents, it was not possible to use polio–measles staff or resources for 
bacterial meningitis diagnostic testing. Moreover, bacteriology laboratories at all levels 
suffered from long-standing deficiencies in equipment, quality assurance and quality control, 
data management skills and training. Thus, the approach for AMES surveillance did not 
appear to offer greater efficiencies than the current sentinel networks that have supported 
IBD surveillance in many countries and regions [36,37,10,21,38], although in China this 
project has provided the first population-based IBD surveillance data, which has continued 
to be sustained by the national government. A permanent bacteriology technical advisor at 
SEARO might have improved CSF and data management at the sentinel sites through the 
development of SOPs for CSF and data handling, training, on-site visits, and laboratory 
indicators adapted to bacteriology.
Our evaluation had several limitations. Slight differences among national surveillance 
protocols posed challenges in developing indicator criteria relevant to all three countries, and 
because the indicators were developed after the project ended, data to calculate them were 
not systematically collected during the evaluation period. Because country data sources 
differed, we had difficulty obtaining data for some indicators. Finally, it was not always 
possible to separate performance at start-up from that later in the project.
This multi-country, cross-regional effort to adapt the polio–measles surveillance 
infrastructure for laboratory-supported surveillance of JE and bacterial meningitis adds to a 
growing body of evidence that supports expanding VPD surveillance networks to include 
additional syndromes and supports the GFIMS principle of linking systems [2] and recently 
updated WHO guidelines recommending integration of JE surveillance with that for AFP or 
meningitis [32,39]. Elements facilitating integration include similarities in target age, 
surveillance protocols, specimen requirements, and reporting and data management systems; 
commonalities among laboratory protocols enable rapid capacity development. Successful 
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integration of JE surveillance into an established, functional bacterial meningitis surveillance 
system in Cambodia supports these observations [40]. However, to apply the GFIMS to the 
development of surveillance for bacterial VPDs, enhancement of laboratory capacity for 
bacteriology and appropriate data management are needed to ensure that challenges do not 
bias disease burden estimates downward and delay the introduction of lifesaving vaccines 
[41].
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Indicators used for the evaluation of acute meningitis-encephalitis 








Japanese encephalitis or bacterial meningitis surveillance
1. Training
2. Availability of laboratory resources
3. Data standardization






5. Specimen referral to secondary laboratory
6. Specimen referral to tertiary laboratory
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Location of AMES surveillance sites in Bangladesh and China, and AES surveillance sites 
in India.
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